Tag Archives: NASDAQ:EXEL

Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL) and Nucana (NASDAQ: NCNA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Exelixis (EXEL – Research Report) and Nucana (NCNA – Research Report) with bullish sentiments. Exelixis (EXEL) William Blair analyst Andy Hsieh reiterated

The Pres, Prod Dev & Med Aff & CMO of Exelixis is Exercising Options

Yesterday it was reported that the Pres, Prod Dev & Med Aff & CMO of Exelixis (EXEL – Research Report), Gisela Schwab, exercised options to sell 100,000 EXEL shares at $1.70 a share, for a total transaction value of $1.94M.

Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL), NeuBase Therapeutics (NASDAQ: NBSE) and Theravance Biopharma (NASDAQ: TBPH)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Exelixis (EXEL – Research Report), NeuBase Therapeutics (NBSE – Research Report) and Theravance Biopharma (TBPH – Research Report) with bullish sentiments. Exelixis

Oppenheimer Remains a Buy on Exelixis (EXEL)

Oppenheimer analyst Silvan Tuerkcan maintained a Buy rating on Exelixis (EXEL – Research Report) today and set a price target of $25.00. The company’s shares closed last Monday at $19.40. According to TipRanks.com, Tuerkcan is a 4-star analyst with an

William Blair Keeps a Buy Rating on Exelixis (EXEL)

In a report released today, Andy Hsieh from William Blair reiterated a Buy rating on Exelixis (EXEL – Research Report). The company’s shares closed last Monday at $20.76. According to TipRanks.com, Hsieh is a 4-star analyst with an average return

Exelixis (EXEL) Receives a Buy from Needham

Needham analyst Chad Messer maintained a Buy rating on Exelixis (EXEL – Research Report) today and set a price target of $28.00. The company’s shares closed last Monday at $17.60. According to TipRanks.com, Messer is a 4-star analyst with an